Compare Verisign, Inc. (VRSN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs Zoetis Inc — how do they compare? Verisign, Inc. trades at $288.99 (market cap $26.00B), while Zoetis Inc trades at $73.88 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| VRSN | ZTS | |
|---|---|---|
Market Cap | $26.00B | $31.14B |
Sector | Technology | Health |
52-Week High | $310.00 | $156.76 |
52-Week Low | $211.49 | $71.91 |
Enterprise Value | $27.31B | $38.70B |
Dividend Yield | 1.13% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $282.94, down 3.55% over the past day, with a mixed earnings history including a recent Q2 2026 EPS miss. The stock shows a bullish technical trend with strong moving averages, while fundamentals highlight robust profitability with a net income margin near 50% and revenue growth to $1.66B in 2025. Recent news emphasizes record domain registrations and the delegation of the .web domain, supporting growth outlook.
The outlook remains positive with a consensus price target of $320, reflecting 13% upside, driven by AI-fueled domain demand and pricing power. Risks include contract renewals and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a growth opportunity with manageable execution risks.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
